[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hyperlipoproteinemia-type-iia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":108,"states":109},"Hyperlipoproteinemia, Type IIa",16,9,[8,16,22,29,35,41,47,53,60,66,72,79,84,90,96,102],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06597006","Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia",[12],"Phase 3","RECRUITING","2026-08-26T02:17:39.048487Z","2026-05-05T02:43:27.397757Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06597019","Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia",[12],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:27.126864Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT04941599","2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)",[26],"Phase 2","2026-08-26T02:16:29.226604Z","2026-05-05T02:43:28.484809Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05693701","Multicomponent Intervention Study- Blood Donors With High Cholesterol",[],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:26.916676Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06743659","Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia",[],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:29.677122Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05348564","Comparing Direct vs Indirect Methods for Cascade Screening",[],"2026-08-26T02:15:56.561131Z","2026-05-05T02:43:29.476324Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07470723","The ORIGIN-FH Study",[],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:29.364342Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT06451770","Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia",[57],"Phase 1","2026-08-26T02:17:47.813245Z","2026-07-19T19:36:05.132526Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06439654","Atlantic Lipid Lowering Treatment Optimization Program",[],"2026-08-26T02:19:29.119921Z","2026-05-05T02:43:26.681995Z",{"nct_id":67,"title":68,"phases":69,"status":70,"updated_at":45,"content_modified":71},"NCT07653555","Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCP",[],"NOT_YET_RECRUITING","2026-06-17T19:21:16.686596Z",{"nct_id":73,"title":74,"phases":75,"status":76,"updated_at":77,"content_modified":78},"NCT07102511","Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:16:13.426928Z","2026-07-30T01:46:14.432415Z",{"nct_id":80,"title":81,"phases":82,"status":76,"updated_at":51,"content_modified":83},"NCT04798430","Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction",[12],"2026-07-05T18:42:10.712995Z",{"nct_id":85,"title":86,"phases":87,"status":76,"updated_at":88,"content_modified":89},"NCT05750667","Penn Family Screening for Familial Hypercholesterolemia",[],"2026-08-26T02:17:30.961790Z","2026-06-16T05:54:08.085353Z",{"nct_id":91,"title":92,"phases":93,"status":76,"updated_at":94,"content_modified":95},"NCT05746247","Improving Diagnosis and Clinical Management of Familial Hypercholesterolemia Through Integrated Machine Learning, Implementation Science, and Behavioral Economics",[],"2026-08-03T02:22:55.112436Z","2026-06-16T05:54:08.084896Z",{"nct_id":97,"title":98,"phases":99,"status":76,"updated_at":100,"content_modified":101},"NCT05284513","Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)",[],"2026-08-26T02:18:58.141497Z","2026-06-16T05:54:08.028141Z",{"nct_id":103,"title":104,"phases":105,"status":76,"updated_at":106,"content_modified":107},"NCT06960655","Improving Lipid Optimization Quality and Treatment Options in ASCVD",[],"2026-08-26T02:16:52.995882Z","2026-06-16T05:54:07.844031Z",[],[110],{"state":111,"count":112,"slug":113},"Pennsylvania",4,"pennsylvania"]